Recursion Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Recursion Pharmaceuticals şirketinin toplam hissedar öz sermayesi $933.9M ve toplam borcu $25.0M olup, bu da borç-öz sermaye oranını 2.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $1.3B ve $371.3M dir.

Anahtar bilgiler

2.68%

Borç/özkaynak oranı

US$25.03m

Borç

Faiz karşılama oranı	n/a
Nakit	US$500.45m
Eşitlik	US$933.95m
Toplam yükümlülükler	US$371.29m
Toplam varlıklar	US$1.31b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

This Just In: Analysts Are Boosting Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Outlook for This Year

Mar 02

Recursion Pharmaceuticals Needs A Clinical Breakthrough To Pique Interest

Feb 14

Recursion: Investors Will Need To Be Patient

Jan 10

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Dec 25

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245

Dec 09

Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline

Nov 20

Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week

Nov 10

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk

Nov 08

Recursion: AI Is Only As Good As The Data

Sep 11

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Sep 04

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 12

Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts

Aug 01

Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery

Jun 24

Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must

Jun 14

Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

May 22

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12

Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate

Apr 10

Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)

Mar 20

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: RXRX 'nin kısa vadeli varlıkları ( $584.1M ) kısa vadeli yükümlülüklerini ( $142.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: RXRX şirketinin kısa vadeli varlıkları ( $584.1M ) uzun vadeli yükümlülüklerini ( $229.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: RXRX şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: RXRX 'nin borç/öz sermaye oranı son 5 yılda 10.6% seviyesinden 2.7% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: RXRX şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: RXRX serbest nakit akışı her yıl % 35.5 1.1 yıl yetecek nakit akışına sahip olacaktır.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/29 00:35
Gün Sonu Hisse Fiyatı	2025/05/29 00:00
Kazançlar	2025/03/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Recursion Pharmaceuticals, Inc. 13 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Gal Munda	Berenberg
Gaurav Goparaju	Berenberg
Alec Stranahan	BofA Global Research

Recursion Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Consensus revenue estimates decrease by 14%, EPS upgraded

Price target decreased by 15% to US$7.43

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Recursion Announces Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Recursion Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2025

Recursion Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 05, 2025

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 Trial of REC-4881 in FAP at Digestive Disease Week 2025

New major risk - Share price stability

Healthverity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Recursion: FDA To Replace Animal Testing With AI? - A Small But Necessary Win

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

Recursion: A Look At Near-Term Phase 1b And Phase 2 Catalysts

REC-617 And REC-994 Trials Will Drive Future AI-Driven Drug Discovery Success

Less than half of directors are independent

Recursion Announces Board of Director Changes

Co-Founder exercised options and sold US$259k worth of stock

Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns

Consensus revenue estimates increase by 15%

New major risk - Revenue and earnings growth

This Just In: Analysts Are Boosting Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Outlook for This Year

Recursion Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Full year 2024 earnings: EPS and revenues miss analyst expectations

Recursion Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 28, 2025

Recursion Pharmaceuticals Needs A Clinical Breakthrough To Pique Interest

Co-Founder exercised options and sold US$316k worth of stock

Recursion Reports 12 Month Data from the Phase 2 Study (Sycamore) of Rec-994

Price target decreased by 7.2% to US$9.14

New major risk - Shareholder dilution

Co-Founder exercised options and sold US$287k worth of stock

Recursion: Investors Will Need To Be Patient

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, with Encouraging Patient Response and Favorable Tolerability

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245

Co-Founder exercised options and sold US$286k worth of stock

Recursion Announces First Patient Dosed in Phase 1/2 Clinical Study of REC-1245

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI).

Recursion Appoints Ben Taylor as Chief Financial Officer

Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline

Co-Founder exercised options and sold US$302k worth of stock

Recursion Pharmaceuticals, Inc. Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Recursion Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Co-Founder exercised options and sold US$245k worth of stock

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Recursion: AI Is Only As Good As The Data

Co-Founder exercised options and sold US$244k worth of stock

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Co-Founder notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for approximately $640 million.

Recursion Pharmaceuticals, Inc. Announces to Appoint David Hallett, Ph.D as Chief Scientific Officer

Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts

Co-Founder notifies of intention to sell stock

Price target decreased by 11% to US$11.57

Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) dropped from Russell 3000E Value Index

Recursion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999995 million.

Recursion Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery

Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must

Co-Founder notifies of intention to sell stock

Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

Recursion Announces Completion of NVIDIA-Powered BioHive-2

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Co-Founder notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024

Chief Financial Officer exercised options and sold US$260k worth of stock

Recursion Appoints Najat Khan as Chief R&D Officer and Chief Commercial Officer

Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate

Co-Founder notifies of intention to sell stock